Nxstage Medical (Nasdaq: NXTM) reported earnings on Nov. 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Nxstage Medical met expectations on revenues and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP loss per share dropped.

Margins increased across the board.

Revenue details
Nxstage Medical reported revenue of $61.2 million. The 14 analysts polled by S&P Capital IQ anticipated a top line of $60.9 million on the same basis. GAAP reported sales were 9.4% higher than the prior-year quarter's $55.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.04. The 10 earnings estimates compiled by S&P Capital IQ predicted -$0.06 per share. GAAP EPS were -$0.04 for Q3 against -$0.10 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 38.8%, 380 basis points better than the prior-year quarter. Operating margin was -3.8%, 280 basis points better than the prior-year quarter. Net margin was -4.2%, 520 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $64.8 million. On the bottom line, the average EPS estimate is -$0.04.

Next year's average estimate for revenue is $241.6 million. The average EPS estimate is -$0.28.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 140 members out of 173 rating the stock outperform, and 33 members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Nxstage Medical a green thumbs-up, and nine give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $19.54.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.